Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease, caused by the deterioration of insulin-producing pancreatic beta cells. Autoantibodies against glutamate decarboxylase (GAD-AAb) are essential markers for this autoimmune process. These autoantibodies can be detected in 70-80 percent of newly diagnosed T1DM patients. Predominantly children and adolescents are affected by T1DM.
Medizym® anti-GAD offers:
- Efficient early diagnosis for patients with high risk for T1DM
- Prognosis for first-degree relatives of T1DM patients
- Prognosis for the clinical course (insulin obligation) when diagnosed with “diabetes mellitus”
- Differentiation to late occurring forms of T1DM (LADA) of type 2 Diabetes.